Northwest Biotherapeutics (OTCMKTS:NWBO) Releases Quarterly Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) posted its earnings results on Monday. The biotechnology company reported ($0.02) EPS for the quarter, Zacks reports. The company had revenue of $0.23 million during the quarter.

Northwest Biotherapeutics Price Performance

NWBO stock traded down $0.02 during mid-day trading on Wednesday, reaching $0.21. 3,911,649 shares of the company’s stock were exchanged, compared to its average volume of 3,229,775. Northwest Biotherapeutics has a 12-month low of $0.20 and a 12-month high of $0.57. The stock’s 50 day moving average is $0.26 and its 200 day moving average is $0.28. The company has a market cap of $293.89 million, a price-to-earnings ratio of -2.65 and a beta of -0.52.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.